WHOOP Announces Global Partnership with Cristiano Ronaldo
13.5.2024 13:00:00 EEST | Business Wire | Press release
WHOOP, the human performance company, today announced Cristiano Ronaldo, the legendary football icon, as an official global ambassador and investor. This represents one of Ronaldo's most significant investments to date. Ronaldo joins the company’s growing roster of global ambassador investors, including Patrick Mahomes, Michael Phelps, Eli Manning, Rory McIlroy, and more. Announced earlier this morning on Instagram Live, this partnership signifies the company’s global growth trajectory and commitment to revolutionizing the world of human performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513817139/en/
WHOOP announces global partnership with Cristiano Ronaldo. (Photo: Business Wire)
The partnership between WHOOP and Ronaldo is an obvious one. Ronaldo’s success has been built on an obsession to perform at the highest levels. First to training, last to leave - former teammates speak of his dedication to self improvement having been the driving force behind his success. Cristiano is still performing at a very high level. He was the highest scorer in the World in 2023, is currently the top scorer in the Saudi Pro League, and is preparing for the Euros this summer. Ronaldo and WHOOP will partner on product development and leverage data-driven insights to help deliver the best health and fitness coaching for athletes and humanity broadly.
“Cristiano has been a WHOOP member for a number of years, and we’re proud to strengthen our relationship further through this partnership,” said Will Ahmed, WHOOP Founder and CEO. “Cristiano’s relentless pursuit of improvement and perfection mirrors our mission. We are looking forward to collaborating with him to share unprecedented insights into his training and recovery methods. Together, we'll unveil exciting product collaborations to enhance the WHOOP experience for our members.”
Cristiano Ronaldo, one of the greatest players in the history of football, has achieved unparalleled success across various prestigious football leagues worldwide, including the Premier League (Manchester United 2003-09; 2021-23), LaLiga (Real Madrid 2009-18), Serie A (Juventus 2018-22), and most recently, the Saudi Pro League (Al Nassr 2022-Present). As the leading scorer in the history of top-level association football globally, with 891 goals and counting, Ronaldo has won seven league titles and five UEFA Champions Leagues and is a five-time winner of the Ballon d'Or.
Ronaldo has also represented his home country of Portugal in international competition with the senior team since 2003, appearing in 206 matches to date and scoring 128 goals. His contributions have led Portugal to victory in the UEFA European Championship in 2016 and the UEFA Nations League title in 2019.
“WHOOP has had a transformative impact on my life both on and off the pitch, and I’m honored to join the team as an investor,” said Cristiano Ronaldo. “I wear WHOOP while training, sleeping, and recovering. It’s been one of the most important tools helping me elevate my game and monitor my health. I look forward to working with WHOOP to continue to raise the bar on WHOOP features and coaching.”
The partnership and investment from Ronaldo coincide with the announcement of WHOOP expanding its availability to Gulf Cooperation Council regions - Saudi Arabia, Qatar, Kuwait, Bahrain - in addition to Hong Kong, Israel, Korea, and Taiwan. Furthermore, by the time of the announcement, WHOOP will have extended its shipping services to India, Mexico, and Brazil, ensuring a seamless experience for members across these markets.
For more information on WHOOP x Ronaldo, please visit www.whoop.com/cr7.
ABOUT WHOOP
WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP serves professional athletes, Fortune 500 CEOs, executives, fitness enthusiasts, military personnel, frontline workers, and anyone looking to improve their performance. WHOOP Unite is a comprehensive solution dedicated to supporting organizations across a wide range of industries with coaching, organizational insights, and health programs. Studies show WHOOP can positively change behavior, increase sleep, and improve physiological biomarkers. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. The latest round of financing made WHOOP the world's most valuable standalone wearables company. Visit WHOOP.com for more information and connect with WHOOP on Instagram, Twitter, Facebook, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513817139/en/
Contact information
PRESS CONTACT:
Will McClaran
Jack Taylor PR
whoop@jacktaylorpr.com
GCC PRESS CONTACT:
Aaron Illathu
Jack Taylor PR
aaron@jacktaylorpr.com
+971 585 575 2884
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom